Parkinson’s Disease Mouse Models
Perform in vivo efficacy studies using one of InnoSer’s Parkinson’s Disease Mouse Models
Your Preclinical Parkinson’s Disease Research with InnoSer
✓ Behavioral & Cognitive Tests
✓ Smart Pathological Assessments
✓ Fast Study Initiation
✓ Tailored Study Designs
✓ Dedicated Research Co-oridnators
As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Parkinson’s disease mouse models that are relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs. InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
InnoSer offers multiple Parkinson’s disease mouse models for preclinical research, including MPTP mouse model of Parkinson’s disease, and transgenic alpha-synuclein or seeding alpha synuclein mouse models using recombinant and/or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of Alzheimer’s disease, we recommend you discuss the most appropriate model with our neurology study directors.
InnoSer’s Available Parkinson’s Disease Mouse Models
In Vitro Neurology Assays
Screen your lead candidate compounds using InnoSer’s in vitro neurology assays to progress to preclinical in vivo studies with confidence
NLRP3 Inflammasome Activation Model
Target neuroinflammation in Parkinson’s disease by studying the therapeutic effects on the NLRP3 pathway activation.
MPTP Mouse Model of Parkinson's Disease
InnoSer offers unique services using MPTP-based inducible PD models.
Recently Acquired remynd Portfolio
Take advantage of InnoSer’s expanded neurology CRO services spanning new Alzheimer’s in vivo research models and expertise
Seeding Alpha-Synuclein Models
InnoSer has extensive experience with alpha-synuclein seeding mouse models using both PD patient-derived brain and recombinant seeds.
Transgenic Alpha-Synuclein Models
InnoSer offers fee-for-service transgenic alpha-synuclein mouse models.
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
The People Behind Your Research
Jolien Beekens, PhD, In Vitro Neurology Study Director
With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com